|
Originally published In Press as doi:10.1074/jbc.M106922200 on January 8, 2002
J. Biol. Chem., Vol. 277, Issue 11, 9580-9589, March 15, 2002
Members of the Zyxin Family of LIM Proteins Interact with Members
of the p130Cas Family of Signal Transducers*
Jinseong
Yi,
Susanne
Kloeker,
Christopher C.
Jensen,
Susanne
Bockholt,
Hiroaki
Honda ,
Hisamura
Hirai , and
Mary C.
Beckerle§
From the Huntsman Cancer Institute and Department of Biology,
University of Utah, Salt Lake City, Utah 84112 and the
University of Tokyo, 7-3-1, Hongo, Bunkyo-ku,
Tokyo, 113-8655, Japan
Received for publication, June 23, 2001, and in revised form, December 20, 2001
 |
ABSTRACT |
Integrin binding to extracellular matrix proteins
induces formation of signaling complexes at focal adhesions. Zyxin
co-localizes with integrins at sites of cell-substratum adhesion and is
postulated to serve as a docking site for the assembly of multimeric
protein complexes involved in regulating cell motility. Recently, we
identified a new member of the zyxin family called TRIP6. TRIP6 is
localized at focal adhesions and overexpression of TRIP6 slows cell
migration. In an effort to define the molecular mechanism by which
TRIP6 affects cell migration, the yeast two-hybrid assay was employed to identify proteins that directly bind to TRIP6. This assay revealed that both TRIP6 and zyxin interact with CasL/HEF1, a member of the Cas
family. This association is mediated by the LIM region of the zyxin
family members and the SH2 domain-binding region of CasL/HEF1.
Furthermore, the association between p130Cas and the
two zyxin family members was demonstrated to occur in vivo
by co-immunoprecipitation. Zyxin and Cas family members may cooperate
to regulate cell motility.
 |
INTRODUCTION |
Integrin-mediated cell adhesion to extracellular matrix
(ECM)1 components is crucial
for many cell activities including cell survival, proliferation,
migration, and differentiation (1-5). Upon binding to the substratum,
integrins recruit many cytoskeletal components to the sites of cell
adhesion and establish a structural link between the elements of the
ECM and actin filaments. In addition to contributing to the physical
link between the extracellular and intracellular environments, integrin
engagement also regulates several signaling pathways (2, 6, 7).
Although the cytoplasmic domains of integrins do not exhibit any
enzymatic activity, they can activate intracellular signaling pathways
by recruiting a number of signaling proteins to focal adhesions
(8-10).
Recent studies have identified a number of proteins that
participate in integrin-dependent signaling pathways
(10-13). These signaling molecules include non-receptor tyrosine
kinases (14, 15), serine/threonine kinases (7, 16-18), a lipid kinase
(19), protein-tyrosine phosphatases (20-24), and small GTPases in the Ras and Rho families (25-29). In addition to proteins that harbor catalytic domains, integrins recruit several adaptor proteins that
facilitate the assembly of multicomponent signaling complexes (30-32).
For instance, upon substratum adhesion, the adaptor protein p130Cas (p130Crk-associated substrate) is
recruited to integrin-rich sites where it docks several regulatory molecules including Src, Crk, and FAK (focal adhesion kinase) (33-35).
Members of the zyxin family have also been postulated to function in
integrin-mediated signaling (36). Zyxin, the founding member of the
family, is a phosphoprotein that is localized at focal adhesions and
along actin filaments (37, 38). The protein displays an
NH2-terminal proline-rich region, one or more leucine-rich nuclear export signals (depending on the species) and three copies of
the LIM motif at its COOH terminus (Fig. 1A) (36, 39, 40). The NH2-terminal proline-rich region of zyxin displays four
proline-rich repeats that serve as docking sites for Mena (mammalian
Ena) and VASP (vasodilator-activated phosphoprotein) (36, 41, 42), proteins that are postulated to play an important role in the assembly
and dynamics of actin filaments (42-44). Sequences in the
NH2 terminus of zyxin also provide a docking site for the actin-bundling protein, -actinin (45-47), further bolstering a link
between zyxin and elements of the actin cytoskeleton. Consistent with
the possibility that zyxin plays some role in the regulation of the
actin cytoskeleton, targeting of zyxin to the inner leaflet of the
plasma membrane or mitochondria stimulates actin assembly (48, 49). As
is the case for the proline-rich sequences in the NH2
terminus of zyxin, the COOH-terminal LIM domains of zyxin are predicted
to mediate a series of protein-protein interactions (40, 50). Thus far,
two protein binding partners for the triplet LIM series in zyxin have
been identified. The most NH2-terminal LIM domain (LIM1) of
zyxin interacts with members of the cysteine-rich protein family
that play important roles in muscle (40, 51). A second binding partner
of the LIM domains, the serine/threonine kinase h-warts/LATS1, was
recently reported to interact with LIM1-2 of zyxin during mitosis
(52). H-wart/LATS1 is a component of mitotic apparatus and negatively
regulates Cdc2 activity (52). Evidence of an association between zyxin
and a regulator of mitotic progression is consistent with the
postulated role of zyxin in signaling. Moreover, although zyxin is
found at focal adhesions and faintly in the leading edge, it also has
the capacity to shuttle between the cytoplasm and the nucleus (36, 39),
raising the possibility that zyxin may relay information between these
two compartments.
Several years ago, a cDNA sequence that encoded two LIM domains
with a high degree of similarity to those in zyxin was identified in a
screen for proteins that interacted with the thyroid hormone receptor
(53). Although the physiological significance of the interaction
between the thyroid hormone receptor and TRIP6 (thyroid receptor
interacting protein 6) has yet to be confirmed, we became interested in
the protein because of its potential relationship to zyxin. Further
characterization of TRIP6 revealed a similar domain structure to that
of zyxin (54). Additionally, the subcellular distribution of exogenous
TRIP6 was comparable with zyxin (55). These observations suggest that
TRIP6 is a member of the zyxin family.
In an effort to learn more about the function of TRIP6 and its
relationship to zyxin, we examined the subcellular distribution of
endogenous TRIP6, studied the effect of TRIP6 overexpression on cell
migration, and performed a two-hybrid screen to identify potential
TRIP6-binding partners. Here we report that both TRIP6 and zyxin
interact with p130Cas and CasL/HEF1, two members of the Cas
family. Cas family members, p130Cas (56), CasL/HEF1 (human
enhancer of filamentation 1 (57, 58)), and Efs/Sin (embryonal
Fyn-associated substrate/Src interacting protein (59, 60)), are adaptor
proteins that play a role in cell motility. Co-expression of
p130Cas and FAK in Chinese hamster ovary cells increases
cell migration as compared with FAK expression alone (61). Cell
migration is also enhanced by co-expression of p130Cas and
Crk (62). This Cas-Crk mediated stimulation of cell migration is
blocked by expression of p130Cas lacking the Crk-binding
site or by expression of Crk lacking a functional SH2 domain. Targeted
gene disruption studies have also demonstrated that Cas is involved in
the regulation of cell locomotion (63, 64). The assembly of signaling
complexes involving Cas family members has been shown to be crucial for
normal cellular responses to integrin engagement (65). The
demonstration that zyxin and Cas family members are present in the same
molecular complex provides a direct connection between zyxin family
members and Cas-dependent motility.
 |
MATERIALS AND METHODS |
Antibody Preparation
Anti-TRIP6 antibody was generated in New Zealand White rabbits
against a peptide sequence deduced from TRIP6 cDNA sequence analysis (54). The amino acid sequence
10KQPEPARAPQGRAIPR25 conjugated to
maleimide-activated keyhole limpet hemocyanin (Pierce) was immunized
three times by subcutaneous injections and subsequent intravenous
injections at 4-week intervals. The anti-TRIP6 antiserum was affinity
purified using the immunogen peptide linked to Sulfolink gel (Pierce)
according to a method described elsewhere (66). Briefly, the polyclonal
antiserum diluted 1:10 in 10 mM Tris, pH 7.5, was passed
through the column, washed extensively with 10 mM Tris, pH
7.5, and the bound antibodies were eluted with 100 mM
glycine, pH 2.5. Fractions were collected in tubes containing 1 M Tris, pH 8. The antiserum was characterized by
immunoblotting and immunoprecipitation of
[35S]methionine/cysteine-labeled IMR-90 cell lysates
prepared under denaturing conditions.
Cell Labeling and Immunoprecipitation
IMR-90 cells were radiolabeled with
[35S]methionine/cysteine (Tran35S-label; ICN
Biochemicals Inc.) for immunoprecipitation under denaturing conditions.
Metabolic labeling of cells was carried out as described elsewhere
(67). Metabolically labeled cells were washed three times with PBS,
lysed in 250 µl of Laemmli sample buffer with protease inhibitors
(0.1 mM phenylmethylsulfonyl fluoride, 0.1 mM
benzamidine, 1 µg/ml pepstatin A, 1 µg/ml phenanthroline) and
scraped from the dishes. Cell lysates were boiled for 5 min to denature
the proteins and centrifuged at 12,000 × g for 10 min.
Immunoprecipitation was carried out after dilution of the supernatants
in 4 volumes of modified RIPA buffer without SDS (50 mM
Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate) supplemented with protease inhibitors. The lysates were
precleared with protein A-agarose beads. The precleared lysates were
then incubated for 1.5 h at 4 °C with either 5 µl of
anti-TRIP6 antiserum or 5 µl of corresponding preimmune serum and
further incubated for 1 h with protein A-agarose beads. The beads
were washed four times with modified RIPA buffer containing 0.2% SDS and boiled for 5 min in 2 × Laemmli sample buffer. The
immunoprecipitates were resolved on 12.5% SDS-polyacrylamide gels. The
gels were dried and subjected to autoradiography.
For co-immunoprecipitation of interacting proteins from adherent cell
lysates, IMR-90 cells grown on tissue culture dishes in DME
supplemented with 10% fetal bovine serum were washed two times with
PBS and lysed in buffer A (50 mM Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.02% SDS, 0.5 mM
EDTA, protease inhibitors). After incubation on ice for 30 min, the
lysates were centrifuged at 10,000 × g for 15 min and
the soluble fractions were recovered for immunoprecipitation. Lysates
from non-adherent cells were prepared as described elsewhere with a
slight modification (68). Briefly, adherent cells were detached by
trypsinization and washed twice with DME containing 1% fetal bovine
serum. Detached cells were held in suspension for 1 h at 37 °C.
Cells were then collected by centrifugation, washed twice with Hanks'
balanced salt solution and then lysed in buffer A. The lysates were
centrifuged at 12,000 × g for 10 min and supernatants
were collected for immunoprecipitation. The lysates were incubated with
protein A-agarose beads for 1 h at 4 °C and precleared
supernatants were collected after centrifugation. For the zyxin
immunoprecipitation, precleared lysates containing 0.5 mg of protein
were incubated for 2 h at 4 °C with 5 µl of zyxin-specific
antisera or preimmune sera. For the TRIP6 immunoprecipitation, 1.0 mg
of precleared lysates were similarly incubated with 40 µl of
affinity-purified TRIP6 antibody or rabbit IgG as a negative control.
Protein A-agarose beads were added to the mixture and incubated for an
additional hour. The beads were washed four times with 1 ml of buffer A
and the immunoprecipitates were eluted by boiling the beads in 2 × Laemmli sample buffer for 5 min. The immunoprecipitates were
resolved on 7.5 or 12.5% SDS-polyacrylamide gel and transferred onto
nitrocellulose paper for immunoblotting. Zyxin and p130Cas
were detected by the enhanced chemiluminescence detection method using
horseradish peroxidase-linked goat anti-rabbit or anti-mouse immunoglobulins as a secondary reagent (Amersham Biosciences, Inc.).
The blots were then stripped in stripping solution (100 mM
2-mercaptoethanol, 2% SDS, 62.5 mM Tris, pH 6.8) for
1 h at 50 °C and washed three times in TBS, 0.1% Tween.
After stripping, the blots were reprobed with anti-vinculin antibody
(Sigma) and developed using enhanced chemiluminescence.
Immunofluorescence
Indirect immunofluorescence was performed as described
previously (69). Briefly, cells were grown on glass coverslips coated with 100 µg/ml fibronectin (Invitrogen) in DME supplemented with 10%
fetal bovine serum. Coverslips were washed in PBS, fixed for 15 min
with 3.7% formaldehyde in PBS, and permeabilized for 4 min with 0.2%
Triton X-100 in PBS. After washing in Tris-buffered saline (TBS: 50 mM Tris, pH 7.6, 150 mM NaCl), the coverslips were incubated with primary antibodies at 37 °C for 60 to 120 min,
washed for 15 min in TBS, and subsequently incubated with fluorescein
isothiocyanate- or Texas Red-conjugated secondary antibodies. The
coverslips were mounted with gelvatol after washing for 15 min in TBS.
Primary antibodies used in this study included the following: an
affinity purified rabbit polyclonal anti-TRIP6 antibody B59, a rabbit
polyclonal anti-zyxin antibody B38 (1:400), the anti-vinculin
monoclonal antibody hVIN-1 (1:200; Sigma), monoclonal anti-FLAG
antibody (1:600; Sigma), and a rabbit polyclonal anti- -galactosidase antibody (1:1000; Cappel). Secondary antibodies included fluorescein isothiocyanate goat anti-mouse IgG (1:250), fluorescein isothiocyanate goat anti-rabbit IgG (1:500; Cappel), and Texas Red-goat anti-mouse IgG
(1:200; Molecular Probes). Cell images were visualized on a Zeiss
Axiophot microscope.
Expression Plasmid Construction
The 5' end of the human TRIP6 sequence was used to search the
expressed sequence tag data base with the BLAST protocol. One highly
homologous murine cDNA clone (W58878) was obtained from Genome
Systems (St. Louis, MO) and sequenced in its entirety. A FLAG epitope
was engineered on the amino terminus of TRIP6 and subsequently
subcloned into the EcoRI and NotI sites of the
pcDNA3.1 vector (Invitrogen). The construct was verified by DNA sequencing.
Transient Transfection of 10T1/2 Cells
Mouse fibroblasts (10T1/2) were plated at 3.0 × 105 cells/60-mm dish ~22 h prior to transfection. The
cells were co-transfected with 0.5 µg of a reporter construct
encoding -galactosidase and 2 µg of empty expression vector or
vector containing FLAG-TRIP6 cDNA. The transient transfection was
performed using LipofectAMINE Plus (16 µl Plus reagent and 10 µl of
LipofectAMINE, Invitrogen) and cells were allowed to incorporate
cDNA constructs for 4 h. Forty h post-transfection, cells were
prepared for the cell migration assay or harvested in 2 × Laemmli
sample buffer to examine TRIP6 expression by Western analysis. A
polyclonal TRIP6 antibody directed against the murine sequence
(CKQPEPSRLPQGRSLPR) was utilized as the primary antibody. TRIP6 was
visualized by the enhanced chemiluminescence detection method. The
relative amount of TRIP6 expression was quantified by using the Kodak
Image Station 440 CF and Kodak Digital Science 1D 3.0.2 software.
Transfection efficiency was ~35% as measured by X-gal staining.
Haptotaxis Migration Assay
Haptotaxis migration assays were performed as previously
described (62). Briefly, cell migration assays were executed using modified Boyden chambers (24-well cell culture inserts containing polyethylene terephthalate membranes, 8-µm pores). The underside of
the membrane was coated overnight at 4 °C with bovine serum albumin
or fibronectin (20 µg/ml). The inserts were rinsed one time with PBS
and then placed into the lower chamber containing 750 µl of DMEM plus
10% fetal bovine serum. Cells were harvested with trypsin/EDTA, washed
twice using serum-free DMEM, and resuspended to 5.0 × 105 cells/ml. Approximately 125,000 cells were added to the
top of each migration chamber and allowed to migrate to the underside of the membrane for 6 h at 37 °C, 5% CO2.
Nonmigratory cells on the upper surface of the membrane were
mechanically removed with a cotton swab. Cells attached to the
underside of the membrane were stained with X-gal substrate. Stained
cells were photographed and counted (per field) with an inverted
phase-contrast microscope using a ×10 objective. Background
migration was determined by counting the number of
-galactosidase-expressing cells migrating on bovine serum albumin.
These values were subtracted from the number of transfected cells
migrating on fibronectin. Each determination represents the average of
three individual wells and error bars represent the standard
error of the mean.
Yeast Two-hybrid Screen
Strains, Plasmids, and Library--
The Saccharomyces
cerevisiae reporter strain L40 (MATa his3-200 trp1-901
leu2-3,112 ade2 lys2-801am URA3::(lexAop)8-lacZ
LYS2::(lexAop)4-HIS3 (70)) was used for
screening and measurement of reporter gene expression. The yeast strain
DY151 (also known as W303-1B, MAT ade2-1 can1-100 his3-11
leu2-3 trp1-1 ura3-1; (71)) was used in mating assays and to
perform specificity test. The prey plasmid pVP16 and mouse embryo
cDNA library cloned into pVP16 have been described elsewhere (70).
pVP16 contains a selectable marker LEU2. The bait vector
plasmid pBTM116/ADE2 that contains the ADE2 gene and a
selectable marker TRP1 has been described elsewhere (72).
The bait plasmid pBTM116/ADE2-TRIP6LIM(1-2) was constructed by
subcloning a PCR-amplified DNA sequence encoding the first and second
LIM domains of TRIP6 (amino acid residues 276-393) into
EcoRI site of pBTM116/ADE2. Other bait constructs containing each individual LIM domain, LIM(1-2), LIM(2-3), and LIM(1-3) of human zyxin were constructed by subcloning into EcoRI site
of pBTM116/ADE2. p130Cas DNA fragments (the full-length
p130Cas cDNA was kindly provided by Dr. T. Parsons)
encoding a part (amino acid residues 319-471) or all of the SH2
domain-binding substrate region (amino acid residues 212-525) of
p130Cas were subcloned into the NotI site of
pVP16 and BamHI site of pBTM116/ADE2.
Library Screen--
The yeast strain L40 was first transformed
with pBTM116/ADE2-TRIP6LIM(1-2) and isolated on selective medium
lacking tryptophan. The yeast strain was then transformed with mouse
cDNA library by electroporation. An estimated 5 × 106 independent transformants were plated on medium lacking
tryptophan, leucine, uracil, and histidine with 45 mM
3-aminotriazole to select for cells that transactivate the
HIS3 reporter gene. HIS+ clones were grown on medium lacking
tryptophan and leucine for 2 days and then assayed for lacZ
expression after the yeast cells were transferred onto nitrocellulose
filter. HIS+/LacZ+ isolates were grown in tryptophan+/leucine plates
containing 10 mg/liter adenine to eliminate pBTM116/ADE2-TRIP6LIM(1-2)
bait plasmid. Plasmid loss was confirmed by formation of red colonies
and tryptophan auxotrophy. Resulting red and LEU+/TRP isolates
contain only prey plasmids. LEU+/TRP isolates were assayed for
lacZ expression. Yeast containing prey sequences that failed
to activate lacZ in the absence of the bait were then mated
with DY151 strain containing pBTM116/ADE2, pBTM116/ADE2-Lamin, or
original bait plasmid pBTM116/ADE2-TRIP6LIM(1-2). The diploids were
then assayed for activation of the lacZ reporter to
eliminate prey clones that interact nonspecifically with LexA or
LexA-Lamin. The prey sequences that specifically interact with the
TRIP6LIM(1-2) were further tested for interaction with zyxinLIM sequences.
Quantitative -Galactosidase Assay
To measure the relative strength of each two-hybrid interaction,
a quantitative -galactosidase assay was performed. Yeast strains
were grown to stationary phase in selective medium lacking tryptophan
and leucine. The cultures were diluted in 3 ml of fresh medium
(A600 ~ 0.2) and then incubated with shaking
until A600 reached 0.5-0.8. Cells were pelleted
and resuspended in the same volume of Z-buffer (60 mM
Na2HPO4, 40 mM
NaH2PO4, 10 mM KCl, 1 mM MgSO4, 40 mM
-mercaptoethanol). 50 µl of chloroform and 50 µl of 0.1% SDS
were added and vortexed at maximum speed for 30 s. 0.2 ml of fresh
o-nitrophenyl -D-galactopyranoside solution (4 mg/ml in Z-buffer) was added and incubated at 30 °C. The reaction was stopped by adding 0.4 ml of 1 M
Na2CO3 when a yellow color appeared (in 10 to
30 min) and the solution was centrifuged at 14,000 × g
for 10 min. A420 of the supernatants was
monitored and adjusted by timing 1.5 (initial culture volume: total
assay volume). Specific -galactosidase activity (Miller units) was calculated using the following formula: Miller units = A420 × 1000/(A600 × incubation time (min) × culture volume (ml)).
 |
RESULTS |
Endogenous TRIP6 Is Targeted to Focal Adhesions--
We have
recently identified TRIP6 as a member of the zyxin family (54). To
date, three members of the zyxin family have been identified: zyxin,
the lipoma-preferred partner (LPP), and TRIP6 (Fig.
1A). As a first step to study
the cellular function of TRIP6, polyclonal antibodies directed against
amino acid residues 10-25 of human TRIP6 were produced. A Western
immunoblot analysis shows that the anti-TRIP6 antiserum specifically
recognizes a protein doublet with apparent molecular weights of 50,000 and 48,000 (Fig. 1B, middle panel). The
calculated molecular weight of TRIP6 based on cDNA sequence
analysis is 50,300. Similarly, this antiserum specifically
immunoprecipitates a 48-50-kDa protein doublet from a lysate of
[35S]methionine/cysteine-labeled IMR-90 prepared under
denaturing conditions (Fig. 1B, right panel). The
48-50-kDa doublet was not detected by Western immunoblot or
immunoprecipitation when preimmune serum was used (Fig. 1B).
No splice variants of TRIP6 have been identified and thus, the doublet
may result from post-translational modification.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 1.
A, schematic representation
illustrating molecular structures and sequence similarity of zyxin
family proteins: zyxin, LPP, and TRIP6. All zyxin family members
display an NH2-terminal proline-rich region, one or two
nuclear export signal (hatched small boxes), and three
copies of the LIM domain at their COOH termini. Zyxin and LPP contain 4 and 2 FPPPP motifs (small gray boxes), respectively. The
FPPPP motif serves as a binding site for Mena/VASP family proteins.
Zyxin also exhibits -actinin-binding site (black box)
within the NH2-terminal 40 amino acid residues. The amino
acid sequence of the NH2-terminal region and each of the
three LIM domains were compared individually with the sequence of zyxin
and the relationship to zyxin is shown in percentage identity.
B, characterization of the anti-peptide antibody B59
directed against TRIP6. Left panel, Coomassie Blue-stained
gel showing molecular markers (lane 1) and proteins of an
IMR-90 cell lysate (lane 2). Middle panel,
proteins from a parallel gel were transferred to nitrocellulose
membrane and probed with the anti-TRIP6 antibody (B59) and its
corresponding preimmune serum (PRE). A protein doublet of 50 and 48 kDa is specifically recognized by the anti-TRIP6 antiserum, B59.
Right panel, lysates prepared from
[35S]methionine/cysteine-labeled IMR-90 cells were used
for immunoprecipitation using the anti-TRIP6 antibody (B59) and its
corresponding preimmune serum (PRE). The immunoprecipitated
proteins were resolved on a SDS-polyacrylamide gel and visualized by
autoradiography. A protein doublet of 48 and 50 kDa is specifically
immunoprecipitated by the anti-TRIP6 antibody, B59. C,
localization of TRIP6 at focal adhesions. The subcellular localization
of TRIP6 was determined by indirect double immunofluorescence by using
an affinity-purified rabbit polyclonal antibody raised against TRIP6
(left panel) and a mouse monoclonal antibody against
vinculin, used as a marker for focal adhesions (middle
panel). TRIP6 is extensively co-localized with vinculin at focal
adhesions. No focal adhesion staining was detected with preimmune serum
(right panel).
|
|
Epitope-tagged TRIP6 localizes at focal adhesions when expressed in
mammalian cells (73). To confirm the subcellular localization of
endogenous TRIP6, indirect immunofluorescence was carried out using an
affinity purified antibody directed against TRIP6. TRIP6 is extensively
co-localized with vinculin at focal adhesions in human fibroblasts
(Fig. 1C). The subcellular distribution of TRIP6 resembles
that of zyxin and LPP (37, 74).
Cells Overexpressing FLAG-TRIP6 Exhibit Reduced Cell
Migration--
Zyxin has been implicated in cell motility (46). To
evaluate whether TRIP6 plays a role in cell migration, murine TRIP6 was
expressed in mouse fibroblasts. Immunofluorescence analysis of
transfected cells confirmed localization of epitope-tagged TRIP6 to
focal adhesions (Fig. 2, A and
B). The amount of TRIP6 protein was estimated to be
~5-10-fold higher in TRIP6-transfected cell lysates than in
vector-transfected cell lysates (Fig. 2C) as determined by
quantitative Western blot analysis with a murine-specific TRIP6
antibody. The effect of TRIP6 expression on migratory behavior was
assayed using the haptotaxis migration assay (Fig. 2D).
Transient overexpression of TRIP6 resulted in an ~50% decrease in
the number of transfected migrating cells (p = 0.035)
using fibronectin as the extracellular matrix. These findings provide
further evidence that TRIP6 is involved in cellular movement; however,
molecular interactions between TRIP6 and components of the migration
machinery remained to be identified.

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 2.
Overexpression of TRIP6 decreases cell
migration. 10T1/2 cells were transiently transfected with either
empty vector or with vector containing FLAG-TRIP6 cDNA.
A, localization of exogenous TRIP6 was detected by indirect
immunofluorescence using a mouse monoclonal antibody against the FLAG
epitope. B, transfected cells were identified by indirect
immunofluorescence using a polyclonal antibody against
-galactosidase. C, overexpression of TRIP6 was monitored
by Western blot analysis. Proteins from either vector (vector) or
FLAG-TRIP6 (TRIP6) transfected cells were separated by SDS-PAGE,
transferred to nitrocellulose, and probed with an anti-TRIP6 antibody.
D, the haptotaxis migration assay was utilized to monitor
cell migration. Cells were allowed to migrate for 6 h on bovine
serum albumin- or fibronectin-coated membranes. The number of migrating
transfected cells was measured by counting cells on the underside of
the membrane that coexpressed -galactosidase. Each determination
represents the average of three individual wells and error
bars represent the standard error of the mean. This
graph is a representative of one of five experiments. The
TRIP6-expressing cells show a statistically significant decrease in
cell migration over vector-transfected cells (p = 0.0046) as determined by the paired Student's t test.
|
|
Screening for TRIP6-binding Proteins by Yeast Two-hybrid
Method--
To identify protein partners that might cooperate with
TRIP6 to affect motility, we performed an interaction screen using the
yeast two-hybrid system. The LIM region represents the most highly
conserved sequence feature among the three zyxin family members (Fig.
1A) and LIM domains represent well characterized protein-binding sites. Therefore, in an effort to identify new interactive partners for TRIP6 that would likely be relevant for other
zyxin family members as well, we focused our initial efforts on a
screen for proteins that could interact with the LIM region of TRIP6.
We employed a two-hybrid screen based on the activation of two reporter
genes HIS3 and lacZ whose expression is driven by
upstream LexA DNA-binding sites.
In our initial two-hybrid screen, we tried to use the three
COOH-terminal LIM domains of TRIP6. However, LexA-TRIP6LIM(1-3) alone
activated reporter gene expression in yeast as assayed by measuring
-galactosidase activity (data not shown). Deletion of sequences
encoding the third LIM domain of TRIP6 reduced the activation of
reporter gene expression to near background, therefore we used a
LexA-TRIP6LIM(1-2) fusion as the bait in our two-hybrid screen. As
outlined in Fig. 3A, we
screened ~5 million independent cDNA clones that were synthesized
from day 10.5 mouse embryo mRNA by random priming. We isolated 29 HIS+ colonies at day 3.5 and an additional 45 HIS+ colonies at day 4.5 after library transformation and plating on selective medium with 45 mM 3-aminotriazole. Of the 74 HIS+ transformants isolated
in the initial screen, 67 were able to activate the lacZ
reporter gene expression ~20-80-fold higher than the background
level of LexA-TRIP6LIM(1-2). To evaluate the specificity of the
two-hybrid interactions in yeast, we eliminated the
pBTM116/ADE2-TRIP6LIM(1-2) bait plasmid from the 67 HIS+/LacZ+ colonies and the resulting strains were mated to DY151 strains containing a bait plasmid encoding LexA, LexA-Lamin, or
LexA-TRIP6LIM(1-2). Of the 67 prey clones isolated in the primary
screen, 49 retained the ability to interact with LexA-TRIP6LIM(1-2),
but did not interact with LexA or LexA-Lamin. The cDNA inserts from
each of the 49 pVP16-mouse cDNA plasmids were sequenced and
searched for similar sequences. All but 5 cDNA inserts represented
bona fide open reading frames in the correct orientations
for expression. Twenty-eight of the remaining 44 cDNAs were
selected multiple times and shared extensive sequence similarity to
previously identified coding sequences. The proteins isolated multiple
times in our screen for TRIP6-binding proteins include a nuclear
glycoprotein gp210 (75), a highly conserved novel ORF (accession
numbers: AL031282 (human), AE003818 (Drosophila), U18779
(yeast), AE004170 (Vibrio) and U67635
(Methanococcus)), atrophin-1-related protein (76), CasL/HEF1
(57), tropomyosin 4 (77), synaptic GTPase activating protein (78), and
a nuclear protein SON (79) (Table I). To
further characterize the interactions between TRIP6LIM(1-2) and the
seven prey sequences described above, we performed quantitative -galactosidase assays. The yeast strains containing both
LexA-TRIP6LIM(1-2) bait and the prey sequences show dramatically
increased -galactosidase activities relative to the strains
containing LexA-TRIP6LIM(1-2) alone (Fig. 3B).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 3.
A, the yeast two-hybrid method for
identification of binding partners for the LIM regions of TRIP6 and
zyxin. Schematic diagram illustrating the protocol for the isolation of
sequences that specifically interact with TRIP6LIM(1-2) in yeast. B,
relative strength of interactions between prey sequences and
TRIP6LIM(1-2). -Galactosidase activities were measured in total
lysates of yeast cells containing lacZ reporter. The yeast
cells contained bait and prey plasmids as indicated below
the bars. -Galactosidase activity by TRIP6LIM(1-2) is
also shown. The prey sequences are summarized in Table I. Error
bars indicate standard deviation. C, relative
strength of interactions between prey sequences and zyxinLIM(1-3).
-Galactosidase activities were measured in total lysates of yeast
cells containing lacZ reporter. The yeast cells contained
bait and prey plasmids as indicated below the bars.
Error bars indicate standard deviation.
|
|
CasL/HEF1 Interacts with Both TRIP6 and Zyxin in Yeast--
The
LIM region of TRIP6 is very similar in sequence to that of zyxin.
Specifically, the first and second LIM domains of TRIP6 show 46 and
61% sequence identity to the corresponding LIM domains of zyxin (Fig.
1A). Because of this sequence similarity, we tested whether
zyxin could interact with the seven TRIP6-binding partners identified
in the yeast two-hybrid screen. We used a zyxin bait construct that
contains all three LIM domains of zyxin, LexA-zyxinLIM(1-3). LexA-zyxinLIM(1-3) did not exhibit the transcriptional activities by
itself or in the presence of VP16 DNA-binding leader sequence (Fig.
3C). Interestingly, of the seven prey sequences that
interact with TRIP6LIM(1-2), only CasL/HEF1 and the nuclear protein
SON were able to activate lacZ expression with
LexA-zyxinLIM(1-3) (Fig. 3C).
Zyxin LIM(1-2) Are Necessary and Sufficient for the CasL/HEF1
Interaction--
We decided to focus first on the characterization of
the interaction with CasL/HEF1 because, of the seven prey sequences
isolated multiple times in our screen, it showed the greatest capacity to interact with both TRIP6 and zyxin in yeast. In addition, CasL/HEF1 has been reported to localize at focal adhesions like TRIP6 and zyxin
providing further support that these interactions may be physiologically relevant. CasL/HEF1 is a "docking" protein that shows sequence and functional similarity to p130Cas. Both
CasL/HEF1 and p130Cas contain an NH2-terminal
SH3 domain followed by an SH2-binding substrate region and a
COOH-terminal conserved region (57, 58). Previous studies have shown
that CasL/HEF1 interacts with multiple signaling components. The
SH2-binding substrate region recruits a Crk family adaptor protein
called Crkl upon integrin engagement and the SH3 domain interacts with
focal adhesion kinase pp125FAK (57, 80). The COOH-terminal
conserved region interacts with the v-Abl tyrosine kinase in
transformed NIH3T3 cells (57). CasL/HEF1 and p130Cas have
been suggested to play a central role in assembly and coordination of
intracellular signaling components at focal adhesions (57).
We first tested which region of zyxin is required for
the interaction with CasL/HEF1. We used a series of LexA fusion
constructs containing sequences encoding individual or multiple LIM
domains from zyxin (Fig. 4A)
to map the sequences necessary for interaction with CasL/HEF1. Western
immunoblot analysis of the yeast cell lysates using a polyclonal
antibody directed against LexA showed that all the LexA-zyxinLIM fusion
constructs were expressed at comparable levels (data not shown). As can
be seen in Fig. 4B, no individual LIM domain is sufficient
to support robust binding to CasL/HEF1. Rather, multiple LIM domains
appear necessary, with LIM(1-2) showing greater activity than
LIM(2-3).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 4.
A, schematic representation of the
LIM domains of TRIP6 and zyxin fused to LexA. The TRIP6LIM(1-2) fusion
construct was initially used for screening of the mouse embryo cDNA
library. Prey sequences isolated in the screen were further tested for
interaction with LexA-zyxinLIM(1-3) fusion. LexA fusion constructs
containing one or two LIM domains of zyxin were used to determine the
zyxin region that is required for the interaction with prey sequence 3 (CasL/HEF1). B, relative strength of the two-hybrid
interactions between zyxin LIM domains and CasL was measured by
quantitative -galactosidase assay of the yeast cells. The yeast
cells contained VP16/CasL and zyxin LIM fusion sequences as indicated
below the bars.
|
|
CasL/HEF1 is a member of the Cas family that includes
p130Cas and Efs/Sin. All three members display similar
sequence and molecular structure with an NH2-terminal SH3
domain, multiple YXXP motifs that serve as SH2
domain-binding sites, and a COOH-terminal conserved region (56-60)
(Fig. 5). All of the CasL/HEF1 clones
isolated in the yeast two-hybrid screen encode a part of the SH2
domain-binding region and contain 7 out of the 13 YXXP
motifs present in full-length CasL/HEF1 (Fig. 5). The SH2
domain-binding substrate region of p130Cas contains 15 YXXP sequences and is about 55% similar to that of CasL/HEF1. Because of these structural features and the sequence similarity of p130Cas to CasL/HEF1, we tried to test if the
substrate region of p130Cas could interact with the LIM
regions of TRIP6 and zyxin in the yeast. However, it was not possible
to test the ability of p130Cas to interact with TRIP6 or
zyxin using the yeast two-hybrid screen because of protein instability
of the VP16-p130Cas fusion protein and intrinsic
transcriptional activity of LexA-p130Cas fusion proteins
containing the substrate region of p130Cas (data not
shown).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
Amino acid sequence of the prey sequence 3 deduced from nucleotide sequence analysis. The prey sequence 3 encodes a region of the SH2 domain-binding substrate region of
CasL/HEF1. The region contains seven YXXP motifs (in
bold) that may be recognized by the SH2 domains when
tyrosine phosphorylated. Numbers indicate the amino acid
positions in the full-length CasL/HEF1.
|
|
Zyxin Family Members Are Associated with p130Cas in
Mammalian Cells--
To examine the interactions between the zyxin and
the Cas family members in vivo, we performed
co-immunoprecipitation experiments with lysates from IMR-90 human
fibroblasts. The anti-zyxin antibody (B38) was raised against a peptide
derived from human zyxin. By Western immunoblot analysis, this antibody
recognizes zyxin, which migrates at ~80 kDa. We recently determined
that this antibody also recognizes the closely related zyxin family
member, LPP (data not shown). Importantly, the B38 anti-zyxin antibody
does not cross-react with p130Cas (Fig.
6A). As can be seen in Fig.
6B (lane 1), p130Cas is present in
immunoprecipitates performed under nondenaturing conditions using the
anti-zyxin antibody. p130Cas is not detected when the
preimmune serum is used in these native immunoprecipitation experiments
(Fig. 6B, lane 2). The recovery of
p130Cas in the immunoprecipitate with zyxin is specific as
evidenced by the fact that vinculin, another cytoskeletal protein
present in the lysate is not present in the precipitated complex with zyxin and p130Cas. Similarly, p130Cas is
present in protein complexes recovered by native immunoprecipitation using anti-TRIP6 antibody but not control IgG (Fig.
6C).Vinculin is not present in either the anti-zyxin,
anti-TRIP6, or control immunoprecipitates, illustrating the specificity
of the recovery of p130Cas. Importantly, all of these
immunoprecipitates were performed using normal cell lysates, not ones
in which proteins of interest were overexpressed. These data provide
compelling evidence that p130Cas is associated in
vivo with zyxin and TRIP6. We were not able to detect CasL/HEF1 in
the human fibroblast cells used for these immunoprecipitation studies
so it was not possible to assess the association of CasL/HEF1 with
zyxin family members under these conditions.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 6.
The association of zyxin and TRIP6 with
p130Cas in human fibroblasts. A, by
Western immunoblot analysis of total IMR-90 proteins (L),
the anti-zyxin antibody recognizes zyxin/LPP at ~80 kDa and does not
cross-react with p130Cas. B and
C, cell lysates from IMR-90 human fibroblasts contain
p130cas that can be detected by Western blot as a high
molecular weight doublet (panels B and C,
lane L). Such lysates were incubated with anti-zyxin
antibody (Panel B, lane 1), anti-zyxin preimmune
serum (panel B, lane 2), anti-TRIP6 (panel
C, lane 1), or anti-TRIP6 preimmune serum
(panel C, lane 2) and the resulting
immunoprecipitates were probed with anti-Cas antibody (upper
panels) or anti-vinculin antibody (lower panels).
p130Cas is specifically recovered in the immunoprecipitated
complex recovered with anti-zyxin and anti-TRIP6 antibodies. The
absence of vinculin in the immunoprecipitates illustrates that the
co-precipitation of p130Cas with zyxin and TRIP6 is
specific.
|
|
Zyxin and p130Cas Are Associated in a Cell
Adhesion-independent Manner--
As discussed above, both zyxin and
p130Cas are components of focal adhesions. The role of
p130Cas in integrin-mediated signaling pathways has been
extensively studied. It is reported that the tyrosine phosphorylation
levels of p130Cas are regulated by cell adhesion to the ECM
(81, 82) and some of the protein-protein interactions involving
p130Cas are regulated by cell adhesion and tyrosine
phosphorylation (32, 35). To test whether zyxin and p130Cas
interact in an adhesion-dependent manner, we performed a
co-immunoprecipitation assay using the anti-zyxin antiserum (B38) and
compared the ability of zyxin to associate with p130Cas
from the lysates of adherent versus detached IMR-90
fibroblasts. As shown in Fig. 7,
comparable amounts of p130Cas are detected in the
immunoprecipitates prepared from equivalent amounts of total protein
derived from adherent and suspended cells. Preimmune serum fails to
precipitate p130Cas from either adherent or suspended
cells. A comparable amount of zyxin was precipitated from the lysates
of adherent and suspended cells. These data suggest that the
interaction between zyxin and p130Cas is cell
adhesion-independent.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 7.
The association of zyxin and
p130Cas is not dependent on cell adhesion. Cell
lysates prepared from adherent or detached IMR-90 cells were
immunoprecipitated with the antiserum against zyxin, B38, or
corresponding preimmune serum (PRE). The immunoprecipitated
proteins were analyzed with an anti-p130Cas antibody or the
B38 anti-zyxin antiserum.
|
|
p130Cas Is Not Necessary for the Targeting of Zyxin to
Focal Adhesions--
Recently it has been determined that the LIM
region of zyxin is both necessary and sufficient for targeting of zyxin
to focal adhesions. Furthermore, at least two LIM domains, either
LIM(1-2) or LIM(2-3), are required for focal adhesion localization of
zyxin (83). Because the interaction between members of the zyxin family and the Cas family is mediated substantially by the first two LIM
domains of zyxin, we examined whether zyxin's ability to interact with
p130Cas is critical for its recruitment to focal adhesions.
To evaluate this possibility, we have compared the subcellular
distributions of zyxin in mouse fibroblasts derived from wild-type and
p130Cas-null mice. During the early stages of wild-type
cell spreading, zyxin is found in focal adhesions, along actin stress
fibers, and in punctate structures at the leading edge (Fig.
8A). The punctate structures
along the leading edge are focal complexes, adhesive structures that
are typically found at the base of ruffling lamellipodia (84). No
difference in protein composition has yet been reported between focal
adhesions and focal complexes (85). However, focal complexes are
morphologically distinct from focal adhesions in that focal complexes
display small punctate or oblong structures. In addition, focal
complexes are highly dynamic relative to focal adhesions (84). In
wild-type cells, membrane protrusion is associated with the formation
of zyxin-containing focal complexes at the leading edge. In
p130Cas-deficient cells, zyxin is prominently localized at
focal adhesions. However, zyxin-rich focal complexes are not detected
in p130Cas-deficient cells (Fig. 8B). Staining
with an anti-vinculin antibody likewise failed to reveal the presence
of focal complexes along the leading edge in
p130Cas-deficient cells, although the cells clearly display
membrane protrusion beyond focal adhesions (data not shown). This
result demonstrates that p130Cas is not necessary for the
focal adhesion targeting of zyxin. The absence of detectable focal
complexes in the p130Cas-deficient cells supports a role
for Cas in assembly, maintenance, or dynamics of focal complexes.

View larger version (74K):
[in this window]
[in a new window]
|
Fig. 8.
The subcellular localization of zyxin in
p130Cas-deficient cells. Mouse fibroblasts derived
from wild type (A) and p130Cas-deficient
(B) mice were plated on fibronectin-coated coverslips and
the subcellular localization of zyxin was determined by an indirect
immunofluorescence method. In wild-type cells, zyxin is localized at
focal adhesions and focal complexes along the leading edge. However,
zyxin staining at focal complexes is not detected in
p130Cas-deficient cells.
|
|
 |
DISCUSSION |
Based on sequence similarity and overall molecular structure, we
have previously identified TRIP6 as a member of the zyxin family. In
this study, we report that like zyxin, endogenous TRIP6 is localized at
focal adhesions. We also demonstrate that overexpression of TRIP6
results in decreased cell migration. To define possible molecular
mechanisms by which TRIP6 influences cell motility, the yeast
two-hybrid system was utilized to identify TRIP6-binding partners. This
study revealed that both TRIP6 and zyxin are able to interact with the
Cas family of focal adhesion proteins. The interactions are mediated
primarily by LIM(1-2) of TRIP6 and zyxin. The LIM region is the most
conserved region among zyxin family members (Fig. 1A).
LIM(1-2) region of TRIP6, used in our two-hybrid screen, is more
closely related to that of LPP than to zyxin. Specifically, LIM1 and
LIM2 of TRIP6 display 61 and 77% sequence identity to the
corresponding LIM domains of LPP and 46 and 61% sequence identity to
those of zyxin. In fact, most of the amino acid residues of LIM(1-2)
conserved between TRIP6 and zyxin are conserved in LPP. This structural
feature as well as focal adhesion localization of LPP suggests that LPP
may be able to interact with the Cas family members. Thus it will be of
interest to test whether LPP can interact with Cas family proteins and
to study the general role of the zyxin family in the regulation of
Cas-mediated signaling events.
One specific function associated with the LIM region of the zyxin
family is targeting to the focal adhesion. In a recent study, Nix and
colleagues (83) have shown that the LIM region of zyxin is both
necessary and sufficient for the targeting of zyxin to focal adhesions
whereas the proline-rich NH2-terminal region alone is
targeted to the leading edge. At least two copies of the LIM domains,
LIM(1-2) or LIM(2-3), are required for focal adhesion targeting (83).
These results raised the possibility that focal adhesion components
that interact with the LIM region of zyxin, such as
p130Cas, are good candidates to recruit zyxin and its
related sequences to focal adhesions. However, zyxin's localization at
focal adhesions and along the actin cytoskeleton was not affected in
the p130Cas-deficient cells. LPP also retained the ability
to localize at focal adhesions (data not shown). The localization of
TRIP6 in p130Cas-deficient cells could not be tested
because our anti-TRIP6 antibody fails to recognize murine TRIP6. Our
results indicate that p130Cas is not absolutely required
for focal adhesion localization of zyxin and LPP. It remains a
possibility that the p130Cas-related proteins, CasL/HEF1
and/or Efs/Sin, may compensate for the loss of p130Cas and
play a role in targeting of zyxin family members to focal adhesions.
Although the LIM(1-2) regions of zyxin and TRIP6 bind to the substrate
region of the Cas family that contains a number of tyrosine
phosphorylation sites, the interaction does not seem to require
tyrosine phosphorylation. A number of studies have demonstrated that
tyrosine phosphorylation of Cas family proteins is enhanced upon cell
adhesion to ECM (81, 82). In our study, we demonstrated that the
association between zyxin and p130Cas is not enhanced by
cell adhesion to ECM, an observation that suggests that the association
is independent of the p130Cas tyrosine phosphorylation
status. Furthermore, because budding yeast exhibit very low levels of
tyrosine kinase activity, it is unlikely that interactions detected in
yeast two-hybrid screens would be dependent on this modification
(86).
The CasL/HEF1 sequence we isolated in the yeast two hybrid screen
exhibits seven YXXP motifs including five of seven consensus sequences for binding to the Crk SH2 domain (57). Interestingly, this
result raises the possibility that the binding site for zyxin and TRIP6
on p130Cas may overlap with Crk's-binding site. If so,
zyxin and TRIP6 may be involved in the regulation of the Cas-Crk
interaction and therefore, downstream signaling pathways. Cas-Crk
association has been demonstrated to play an important role in membrane
ruffling and cell migration on ECM by activating the Rac signaling
pathway (62). Data presented in this report establishes that
overexpression of TRIP6 inhibits cell migration. One reasonable
hypothesis based on these observations is that overexpression of TRIP6
results in excessive sequestration of cellular p130Cas,
perhaps preventing the p130Cas-Crk interaction, and
blocking downstream signaling events. Our data are consistent with the
hypothesis that TRIP6 can inhibit cell migration by disrupting Cas/Crk
signaling; however, other experiments will be necessary to test this
model. For example, in future work, it will be important to determine
if Cas/Crk/TRIP6 can co-exist in a macromolecular complex and to
explore whether TRIP6 overexpression has any effect on the Cas-Crk interaction.
Focal adhesions persist in p130Cas-deficient cells;
however, by either anti-zyxin or anti-vinculin staining (data not
shown), focal complex structures at the leading edge are absent. Based on this observation, p130Cas appears to be essential to
maintain a typical ratio of focal complexes to focal adhesions. A
recent study revealed that focal complex and focal adhesion formation
is regulated by two distinct signaling pathways, the Rac and Rho
pathways (85). Focal complex formation is initiated by activation of
the Rac pathway and is independent of Rho, which plays an important
role in the assembly of focal adhesions and actin stress fibers (84).
Rac and Rho pathways are mutually antagonistic in focal complex and
focal adhesion assembly (85). Down-regulation of Rho activity leads to
the up-regulation of Rac activity and thus shifts the adhesion pattern
from focal adhesions to focal complexes. In contrast, down-regulation
of Rac results in the loss of focal complexes and the growth of
Rho-mediated focal adhesions. Based on this mutual antagonism between
the Rho and Rac pathways, the apparent absence of focal complexes at
the leading edges of p130Cas-null cells raises the
possibility that p130Cas may play a role as a positive
regulator of the Rac signaling pathway and focal complex formation. In
support of this possibility, it has been demonstrated that
p130Cas-mediated cell migration requires the adaptor
protein Crk (62) and the association of p130Cas and Crk
leads to the activation of the Rac-JNK (c-Jun NH2-terminal kinase) signaling pathway (87, 88). Thus deletion of
p130Cas may lead to the up-regulation of Rho activity and
the preferential establishment of focal adhesions. Since zyxin family
members can associate directly with Cas proteins, they may cooperate
with Cas family members to regulate cell adhesion and motility.
 |
ACKNOWLEDGEMENTS |
We acknowledge the expert graphics and
editorial advice of Diana Lim and Jenny Jensen.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant GM50877 (to M. C. B.), National Research Service Awards
(to S. K. and S. B.), the Huntsman Cancer Foundation, and the
University of Utah DNA-Peptide Facility and Sequencing Facility
technical support Grant CA42014.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Huntsman Cancer
Institute, 2000 Circle of Hope, University of Utah, Salt Lake City, UT
84112. Tel.: 801-581-4485; Fax: 801-581-2175; E-mail: mary.beckerle@hci.utah.edu.
Published, JBC Papers in Press, January 8, 2002, DOI 10.1074/jbc.M106922200
 |
ABBREVIATIONS |
The abbreviations used are:
ECM, extracellular matrix;
Cas, Crk-associated substrate;
FAK, focal
adhesion kinase;
PBS, phosphate-buffered saline;
DMEM, Dulbecco's
modified Eagle's medium;
X-gal, 5-bromo-4-chloro-3-indolyl
-D-galactopyranoside;
LPP, lipoma-preferred partner;
SH3, Src homology domain 3;
TRIP6, thyroid receptor interacting protein
6.
 |
REFERENCES |
| 1.
|
Adams, J. C.,
and Watt, F. M.
(1993)
Development
117,
1183-1198[Medline]
[Order article via Infotrieve]
|
| 2.
|
Giancotti, F. G.,
and Ruoslahti, E.
(1999)
Science
285,
1028-1032[Abstract/Free Full Text]
|
| 3.
|
Meredith, J. J.,
and Schwartz, M. A.
(1997)
Trends Cell Biol.
7,
146-150[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Meredith, J. E., Jr.,
Fazeli, B.,
and Schwartz, M. A.
(1993)
Mol. Biol. Cell
4,
953-961[Abstract]
|
| 5.
|
Frisch, S. M.,
and Francis, H.
(1994)
J. Cell Biol.
124,
619-626[Abstract/Free Full Text]
|
| 6.
|
Aplin, A. E.,
Howe, A.,
Alahari, S. K.,
and Juliano, R. L.
(1998)
Pharmacol. Rev.
50,
197-263[Abstract/Free Full Text]
|
| 7.
|
Zhu, X.,
and Assoian, R. K.
(1995)
Mol. Biol. Cell
6,
273-282[Abstract]
|
| 8.
|
Yamada, K. M.,
and Miyamoto, S.
(1995)
Curr. Opin. Cell Biol.
7,
681-689[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Sastry, S. K.,
and Horwitz, A. F.
(1993)
Curr. Opin. Cell Biol.
5,
819-831[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Clark, E. A.,
and Brugge, J. S.
(1995)
Science
268,
233-239[Abstract/Free Full Text]
|
| 11.
|
Kumar, C. C.
(1998)
Oncogene
17,
1365-1373[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Juliano, R. L.,
and Haskill, S.
(1993)
J. Cell Biol.
120,
577-585[Free Full Text]
|
| 13.
|
Schwartz, M. A.,
Schaller, M. D.,
and Ginsberg, M. H.
(1995)
Annu. Rev. Cell Dev. Biol.
11,
549-599[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Lewis, J. M.,
Baskaran, R.,
Taagepera, S.,
Schwartz, M. A.,
and Wang, J. Y.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
15174-15179[Abstract/Free Full Text]
|
| 15.
|
Lewis, J. M.,
and Schwartz, M. A.
(1998)
J. Biol. Chem.
273,
14225-14230[Abstract/Free Full Text]
|
| 16.
|
Vuori, K.,
and Ruoslahti, E.
(1993)
J. Biol. Chem.
268,
21459-21462[Abstract/Free Full Text]
|
| 17.
|
Chen, Q.,
Kinch, M. S.,
Lin, T. H.,
Burridge, K.,
and Juliano, R. L.
(1994)
J. Biol. Chem.
269,
26602-26605[Abstract/Free Full Text]
|
| 18.
|
Defilippi, P.,
Venturino, M.,
Gulino, D.,
Duperray, A.,
Boquet, P.,
Fiorentini, C.,
Volpe, G.,
Palmieri, M.,
Silengo, L.,
and Tarone, G.
(1997)
J. Biol. Chem.
272,
21726-21734[Abstract/Free Full Text]
|
| 19.
|
King, W. G.,
Mattaliano, M. D.,
Chan, T. O.,
Tsichlis, P. N.,
and Brugge, J. S.
(1997)
Mol. Cell. Biol.
17,
4406-4418[Abstract]
|
| 20.
|
Angers-Loustau, A.,
Cote, J. F.,
Charest, A.,
Dowbenko, D.,
Spencer, S.,
Lasky, L. A.,
and Tremblay, M. L.
(1999)
J. Cell Biol.
144,
1019-1031[Abstract/Free Full Text]
|
| 21.
|
Garton, A. J.,
and Tonks, N. K.
(1999)
J. Biol. Chem.
274,
3811-3818[Abstract/Free Full Text]
|
| 22.
|
Garton, A. J.,
Flint, A. J.,
and Tonks, N. K.
(1996)
Mol. Cell. Biol.
16,
6408-6418[Abstract]
|
| 23.
|
Liu, F.,
Hill, D. E.,
and Chernoff, J.
(1996)
J. Biol. Chem.
271,
31290-31295[Abstract/Free Full Text]
|
| 24.
|
Tamura, M., Gu, J.,
Danen, E. H.,
Takino, T.,
Miyamoto, S.,
and Yamada, K. M.
(1999)
J. Biol. Chem.
274,
20693-20703[Abstract/Free Full Text]
|
| 25.
|
Mainiero, F.,
Murgia, C.,
Wary, K. K.,
Curatola, A. M.,
Pepe, A.,
Blumemberg, M.,
Westwick, J. K.,
Der, C. J.,
and Giancotti, F. G.
(1997)
EMBO J.
16,
2365-2375[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Barry, S. T.,
Flinn, H. M.,
Humphries, M. J.,
Critchley, D. R.,
and Ridley, A. J.
(1997)
Cell Adhes. Commun.
4,
387-398[Medline]
[Order article via Infotrieve]
|
| 27.
|
Clark, E. A.,
King, W. G.,
Brugge, J. S.,
Symons, M.,
and Hynes, R. O.
(1998)
J. Cell Biol.
142,
573-586[Abstract/Free Full Text]
|
| 28.
|
Ren, X. D.,
Kiosses, W. B.,
and Schwartz, M. A.
(1999)
EMBO J.
18,
578-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Renshaw, M. W.,
Toksoz, D.,
and Schwartz, M. A.
(1996)
J. Biol. Chem.
271,
21691-21694[Abstract/Free Full Text]
|
| 30.
|
Schlaepfer, D. D.,
Hanks, S. K.,
Hunter, T.,
and van der Geer, P.
(1994)
Nature
372,
786-791[Medline]
[Order article via Infotrieve]
|
| 31.
|
Schaller, M. D.,
and Parsons, J. T.
(1995)
Mol. Cell. Biol.
15,
2635-2645[Abstract]
|
| 32.
|
Vuori, K.,
Hirai, H.,
Aizawa, S.,
and Ruoslahti, E.
(1996)
Mol. Cell. Biol.
16,
2606-2613[Abstract]
|
| 33.
|
Burnham, M. R.,
Harte, M. T.,
Richardson, A.,
Parsons, J. T.,
and Bouton, A. H.
(1996)
Oncogene
12,
2467-2472[Medline]
[Order article via Infotrieve]
|
| 34.
|
Harte, M. T.,
Hildebrand, J. D.,
Burnham, M. R.,
Bouton, A. H.,
and Parsons, J. T.
(1996)
J. Biol. Chem.
271,
13649-13655[Abstract/Free Full Text]
|
| 35.
|
Polte, T. R.,
and Hanks, S. K.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10678-10682[Abstract/Free Full Text]
|
| 36.
|
Beckerle, M. C.
(1997)
Bioessays
19,
949-957[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Crawford, A. W.,
and Beckerle, M. C.
(1991)
J. Biol. Chem.
266,
5847-5853[Abstract/Free Full Text]
|
| 38.
|
Macalma, T.,
Otte, J.,
Hensler, M. E.,
Bockholt, S. M.,
Louis, H. A.,
Kalff-Suske, M.,
Grzeschik, K. H.,
von der Ahe, D.,
and Beckerle, M. C.
(1996)
J. Biol. Chem.
271,
31470-31478[Abstract/Free Full Text]
|
| 39.
|
Nix, D. A.,
and Beckerle, M. C.
(1997)
J. Cell Biol.
138,
1139-1147[Abstract/Free Full Text]
|
| 40.
|
Sadler, I.,
Crawford, A. W.,
Michelsen, J. W.,
and Beckerle, M. C.
(1992)
J. Cell Biol.
119,
1573-1587[Abstract/Free Full Text]
|
| 41.
|
Golsteyn, R. M.,
Beckerle, M. C.,
Koay, T.,
and Friederich, E.
(1997)
J. Cell Sci.
110,
1893-1906[Abstract]
|
| 42.
|
Niebuhr, K.,
Ebel, F.,
Frank, R.,
Reinhard, M.,
Domann, E.,
Carl, U. D.,
Walter, U.,
Gertler, F. B.,
Wehland, J.,
and Chakraborty, T.
(1997)
EMBO J.
16,
5433-5444[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Laurent, V.,
Loisel, T. P.,
Harbeck, B.,
Wehman, A.,
Grobe, L.,
Jockusch, B. M.,
Wehland, J.,
Gertler, F. B.,
and Carlier, M. F.
(1999)
J. Cell Biol.
144,
1245-1258[Abstract/Free Full Text]
|
| 44.
|
Reinhard, M.,
Jouvenal, K.,
Tripier, D.,
and Walter, U.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7956-7960[Abstract/Free Full Text]
|
| 45.
|
Crawford, A. W.,
Michelsen, J. W.,
and Beckerle, M. C.
(1992)
J. Cell Biol.
116,
1381-1393[Abstract/Free Full Text]
|
| 46.
|
Drees, B. E.,
Andrews, K. M.,
and Beckerle, M. C.
(1999)
J. Cell Biol.
147,
1549-1560[Abstract/Free Full Text]
|
| 47.
|
Reinhard, M.,
Zumbrunn, J.,
Jaquemar, D.,
Kuhn, M.,
Walter, U.,
and Trueb, B.
(1999)
J. Biol. Chem.
274,
13410-13418[Abstract/Free Full Text]
|
| 48.
|
Drees, B.,
Friederich, E.,
Fradelizi, J.,
Louvard, D.,
Beckerle, M. C.,
and Golsteyn, R. M.
(2000)
J. Biol. Chem.
275,
22503-22511[Abstract/Free Full Text]
|
| 49.
|
Fradelizi, J.,
Noireaux, V.,
Plastino, J.,
Menichi, B.,
Louvard, D.,
Sykes, C.,
Golsteyn, R. M.,
and Friederich, E.
(2001)
Nat. Cell Biol.
3,
699-707[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Schmeichel, K. L.,
and Beckerle, M. C.
(1994)
Cell
79,
211-219[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Arber, S.,
Halder, G.,
and Caroni, P.
(1994)
Cell
79,
221-231[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Hirota, T.,
Morisaki, T.,
Nishiyama, Y.,
Marumoto, T.,
Tada, K.,
Hara, T.,
Masuko, N.,
Inagaki, M.,
Hatakeyama, K.,
and Saya, H.
(2000)
J. Cell Biol.
149,
1073-1086[Abstract/Free Full Text]
|
| 53.
|
Lee, J. W.,
Choi, H. S.,
Gyuris, J.,
Brent, R.,
and Moore, D. D.
(1995)
Mol. Endocrinol.
9,
243-254[Abstract/Free Full Text]
|
| 54.
|
Yi, J.,
and Beckerle, M. C.
(1998)
Genomics
49,
314-316[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Zhao, M. K.,
Wang, Y.,
Murphy, K., Yi, J.,
Beckerle, M. C.,
and Gilmore, T. D.
(1999)
Gene Expr.
8,
207-217[Medline]
[Order article via Infotrieve]
|
| 56.
|
Sakai, R.,
Iwamatsu, A.,
Hirano, N.,
Ogawa, S.,
Tanaka, T.,
Mano, H.,
Yazaki, Y.,
and Hirai, H.
(1994)
EMBO J.
13,
3748-3756[Medline]
[Order article via Infotrieve]
|
| 57.
|
Law, S. F.,
Estojak, J.,
Wang, B.,
Mysliwiec, T.,
Kruh, G.,
and Golemis, E. A.
(1996)
Mol. Cell. Biol.
16,
3327-3337[Abstract]
|
| 58.
|
Minegishi, M.,
Tachibana, K.,
Sato, T.,
Iwata, S.,
Nojima, Y.,
and Morimoto, C.
(1996)
J. Exp. Med.
184,
1365-1375[Abstract/Free Full Text]
|
| 59.
|
Ishino, M.,
Ohba, T.,
Sasaki, H.,
and Sasaki, T.
(1995)
Oncogene
11,
2331-2338[Medline]
[Order article via Infotrieve]
|
| 60.
|
Alexandropoulos, K.,
and Baltimore, D.
(1996)
Genes Dev.
10,
1341-1355[Abstract/Free Full Text]
|
| 61.
|
Cary, L. A.,
Han, D. C.,
Polte, T. R.,
Hanks, S. K.,
and Guan, J. L.
(1998)
J. Cell Biol.
140,
211-221[Abstract/Free Full Text]
|
| 62.
|
Klemke, R. L.,
Leng, J.,
Molander, R.,
Brooks, P. C.,
Vuori, K.,
and Cheresh, D. A.
(1998)
J. Cell Biol.
140,
961-972[Abstract/Free Full Text]
|
| 63.
|
Honda, H.,
Oda, H.,
Nakamoto, T.,
Honda, Z.,
Sakai, R.,
Suzuki, T.,
Saito, T.,
Nakamura, K.,
Nakao, K.,
Ishikawa, T.,
Katsuki, M.,
Yazaki, Y.,
and Hirai, H.
(1998)
Nat. Genet.
19,
361-365[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Honda, H.,
Nakamoto, T.,
Sakai, R.,
and Hirai, H.
(1999)
Biochem. Biophys. Res. Commun.
262,
25-30[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
O'Neill, G. M.,
Fashena, S. J.,
and Golemis, E. A.
(2000)
Trends Cell Biol.
10,
111-119[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Harlow, A.,
and Lane, D.
(1988)
Antibodies: A Laboratory Manual
, pp. 313-315, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 67.
|
Pomies, P.,
Louis, H. A.,
and Beckerle, M. C.
(1997)
J. Cell Biol.
139,
157-168[Abstract/Free Full Text]
|
| 68.
|
Polte, T. R.,
and Hanks, S. K.
(1997)
J. Biol. Chem.
272,
5501-5509[Abstract/Free Full Text]
|
| 69.
|
Beckerle, M. C.
(1986)
J. Cell Biol.
103,
1679-1687[Abstract/Free Full Text]
|
| 70.
|
Hollenberg, S. M.,
Sternglanz, R.,
Cheng, P. F.,
and Weintraub, H.
(1995)
Mol. Cell. Biol.
15,
3813-3822[Abstract]
|
| 71.
|
Thomas, B. J.,
and Rothstein, R.
(1989)
Cell
56,
619-630[CrossRef][Medline]
[Order article via Infotrieve]
|
| 72.
|
McCright, B.,
and Virshup, D. M.
(1995)
J. Biol. Chem.
270,
26123-26128[Abstract/Free Full Text]
|
| 73.
|
Wang, Y.,
Dooher, J. E.,
Koedood Zhao, M.,
and Gilmore, T. D.
(1999)
Gene (Amst.)
234,
403-409[CrossRef][Medline]
[Order article via Infotrieve]
|
| 74.
|
Petit, M. M.,
Fradelizi, J.,
Golsteyn, R. M.,
Ayoubi, T. A.,
Menichi, B.,
Louvard, D.,
Van De Ven, W. J.,
and Friederich, E.
(2000)
Mol. Biol. Cell
11,
117-129[Abstract/Free Full Text]
|
| 75.
|
Greber, U. F.,
Senior, A.,
and Gerace, L.
(1990)
EMBO J.
9,
1495-1502[Medline]
[Order article via Infotrieve]
|
| 76.
|
Seki, N.,
Ohira, M.,
Nagase, T.,
Ishikawa, K.,
Miyajima, N.,
Nakajima, D.,
Nomura, N.,
and Ohara, O.
(1997)
DNA Res.
4,
345-349[Abstract]
|
| 77.
|
Yamawaki-Kataoka, Y.,
and Helfman, D. M.
(1987)
J. Biol. Chem.
262,
10791-10800[Abstract/Free Full Text]
|
| 78.
|
Kim, J. H.,
Liao, D.,
Lau, L. F.,
and Huganir, R. L.
(1998)
Neuron
20,
683-691[CrossRef][Medline]
[Order article via Infotrieve]
|
| 79.
|
Shimada, K.,
Harata, M.,
and Mizuno, S.
(1997)
J. Cell Sci.
110,
3031-3041[Abstract]
|
| 80.
|
Astier, A.,
Manie, S. N.,
Law, S. F.,
Canty, T.,
Haghayghi, N.,
Druker, B. J.,
Salgia, R.,
Golemis, E. A.,
and Freedman, A. S.
(1997)
Leuk. Lymphoma
28,
65-72[Medline]
[Order article via Infotrieve]
|
| 81.
|
Petch, L. A.,
Bockholt, S. M.,
Bouton, A.,
Parsons, J. T.,
and Burridge, K.
(1995)
J. Cell Sci.
108,
1371-1379[Abstract]
|
| 82.
|
Nojima, Y.,
Morino, N.,
Mimura, T.,
Hamasaki, K.,
Furuya, H.,
Sakai, R.,
Sato, T.,
Tachibana, K.,
Morimoto, C.,
Yazaki, Y.,
and Hirai, H.
(1995)
J. Biol. Chem.
270,
15398-15402[Abstract/Free Full Text]
|
| 83.
|
Nix, D. A.,
Fradelizi, J.,
Bockholt, S.,
Menichi, B.,
Louvard, D.,
Friederich, E.,
and Beckerle, M. C.
(2001)
J. Biol. Chem.
276,
34759-34767[Abstract/Free Full Text]
|
| 84.
|
Nobes, C. D.,
and Hall, A.
(1995)
Cell
81,
53-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 85.
|
Rottner, K.,
Hall, A.,
and Small, J. V.
(1999)
Curr. Biol.
9,
640-648[CrossRef][Medline]
[Order article via Infotrieve]
|
| 86.
|
Keegan, K.,
and Cooper, J. A.
(1996)
Oncogene
12,
1537-1544[Medline]
[Order article via Infotrieve]
|
| 87.
|
Dolfi, F.,
Garcia-Guzman, M.,
Ojaniemi, M.,
Nakamura, H.,
Matsuda, M.,
and Vuori, K.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
15394-15399[Abstract/Free Full Text]
|
| 88.
|
Kiyokawa, E.,
Hashimoto, Y.,
Kobayashi, S.,
Sugimura, H.,
Kurata, T.,
and Matsuda, M.
(1998)
Genes Dev.
12,
3331-3336[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Chastre, M. Abdessamad, A. Kruglov, E. Bruyneel, M. Bracke, Y. Di Gioia, M. C. Beckerle, F. van Roy, and L. Kotelevets
TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness
FASEB J,
March 1, 2009;
23(3):
916 - 928.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Crowley, T. C. Smith, Z. Fang, N. Takizawa, and E. J. Luna
Supervillin Reorganizes the Actin Cytoskeleton and Increases Invadopodial Efficiency
Mol. Biol. Cell,
February 1, 2009;
20(3):
948 - 962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Hirata, H. Tatsumi, and M. Sokabe
Mechanical forces facilitate actin polymerization at focal adhesions in a zyxin-dependent manner
J. Cell Sci.,
September 1, 2008;
121(17):
2795 - 2804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-J. Lai, W.-C. Lin, and F.-T. Lin
PTPL1/FAP-1 Negatively Regulates TRIP6 Function in Lysophosphatidic Acid-induced Cell Migration
J. Biol. Chem.,
August 17, 2007;
282(33):
24381 - 24387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-Y. Bai, M. Ohsugi, Y. Abe, and T. Yamamoto
ZRP-1 controls Rho GTPase-mediated actin reorganization by localizing at cell-matrix and cell-cell adhesions
J. Cell Sci.,
August 15, 2007;
120(16):
2828 - 2837.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Worley, G. S. Nieman, K. Geddes, and F. Heffron
Salmonella typhimurium disseminates within its host by manipulating the motility of infected cells
PNAS,
November 21, 2006;
103(47):
17915 - 17920.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Takizawa, T. C. Smith, T. Nebl, J. L. Crowley, S. J. Palmieri, L. M. Lifshitz, A. G. Ehrhardt, L. M. Hoffman, M. C. Beckerle, and E. J. Luna
Supervillin modulation of focal adhesions involving TRIP6/ZRP-1
J. Cell Biol.,
July 31, 2006;
174(3):
447 - 458.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kostic and M. P. Sheetz
Fibronectin Rigidity Response through Fyn and p130Cas Recruitment to the Leading Edge
Mol. Biol. Cell,
June 1, 2006;
17(6):
2684 - 2695.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Dadke, M. Jarnik, E. N. Pugacheva, M. K. Singh, and E. A. Golemis
Deregulation of HEF1 Impairs M-Phase Progression by Disrupting the RhoA Activation Cycle
Mol. Biol. Cell,
March 1, 2006;
17(3):
1204 - 1217.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Zheng and P. J. McKeown-Longo
Cell adhesion regulates Ser/Thr phosphorylation and proteasomal degradation of HEF1
J. Cell Sci.,
January 1, 2006;
119(1):
96 - 103.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wei, T. E. Gorman, X. Liu, B. Ith, A. Tseng, Z. Chen, D. I. Simon, M. D. Layne, and S.-F. Yet
Increased Neointima Formation in Cysteine-Rich Protein 2-Deficient Mice in Response to Vascular Injury
Circ. Res.,
December 9, 2005;
97(12):
1323 - 1331.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Yoshigi, L. M. Hoffman, C. C. Jensen, H. J. Yost, and M. C. Beckerle
Mechanical force mobilizes zyxin from focal adhesions to actin filaments and regulates cytoskeletal reinforcement
J. Cell Biol.,
October 24, 2005;
171(2):
209 - 215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Muenzner, M. Rohde, S. Kneitz, and C. R. Hauck
CEACAM engagement by human pathogens enhances cell adhesion and counteracts bacteria-induced detachment of epithelial cells
J. Cell Biol.,
August 29, 2005;
170(5):
825 - 836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-J. Lai, C.-S. Chen, W.-C. Lin, and F.-T. Lin
c-Src-Mediated Phosphorylation of TRIP6 Regulates Its Function in Lysophosphatidic Acid-Induced Cell Migration
Mol. Cell. Biol.,
July 15, 2005;
25(14):
5859 - 5868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Pratt, H. Epple, M. Ward, Y. Feng, V. M. Braga, and G. D. Longmore
The LIM protein Ajuba influences p130Cas localization and Rac1 activity during cell migration
J. Cell Biol.,
February 28, 2005;
168(5):
813 - 824.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Li, L.-H. Bin, F. Li, Y. Liu, D. Chen, Z. Zhai, and H.-B. Shu
TRIP6 is a RIP2-associated common signaling component of multiple NF-{kappa}B activation pathways
J. Cell Sci.,
February 1, 2005;
118(3):
555 - 563.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N.-Y. Shin, R. S. Dise, J. Schneider-Mergener, M. D. Ritchie, D. M. Kilkenny, and S. K. Hanks
Subsets of the Major Tyrosine Phosphorylation Sites in Crk-associated Substrate (CAS) Are Sufficient to Promote Cell Migration
J. Biol. Chem.,
September 10, 2004;
279(37):
38331 - 38337.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. P.Y. Lee and C. Y. Cheng
Adaptors, Junction Dynamics, and Spermatogenesis
Biol Reprod,
August 1, 2004;
71(2):
392 - 404.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Sanz-Rodriguez, M. Guerrero-Esteo, L.-M. Botella, D. Banville, C. P. H. Vary, and C. Bernabeu
Endoglin Regulates Cytoskeletal Organization through Binding to ZRP-1, a Member of the Lim Family of Proteins
J. Biol. Chem.,
July 30, 2004;
279(31):
32858 - 32868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. A. Conley, R. Koleva, J. D. Smith, D. Kacer, D. Zhang, C. Bernabeu, and C. P. H. Vary
Endoglin Controls Cell Migration and Composition of Focal Adhesions: FUNCTION OF THE CYTOSOLIC DOMAIN
J. Biol. Chem.,
June 25, 2004;
279(26):
27440 - 27449.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Li, L. Zhuang, and B. Trueb
Zyxin Interacts with the SH3 Domains of the Cytoskeletal Proteins LIM-nebulette and Lasp-1
J. Biol. Chem.,
May 7, 2004;
279(19):
20401 - 20410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Xu, Y.-J. Lai, W.-C. Lin, and F.-T. Lin
TRIP6 Enhances Lysophosphatidic Acid-induced Cell Migration by Interacting with the Lysophosphatidic Acid 2 Receptor
J. Biol. Chem.,
March 12, 2004;
279(11):
10459 - 10468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ilic, B. Kovacic, K. Johkura, D. D. Schlaepfer, N. Tomasevic, Q. Han, J.-B. Kim, K. Howerton, C. Baumbusch, N. Ogiwara, et al.
FAK promotes organization of fibronectin matrix and fibrillar adhesions
J. Cell Sci.,
January 15, 2004;
117(2):
177 - 187.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Marie, S. J. Pratt, M. Betson, H. Epple, J. T. Kittler, L. Meek, S. J. Moss, S. Troyanovsky, D. Attwell, G. D. Longmore, et al.
The LIM Protein Ajuba Is Recruited to Cadherin-dependent Cell Junctions through an Association with alpha -Catenin
J. Biol. Chem.,
January 3, 2003;
278(2):
1220 - 1228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Hoffman, D. A. Nix, B. Benson, R. Boot-Hanford, E. Gustafsson, C. Jamora, A. S. Menzies, K. L. Goh, C. C. Jensen, F. B. Gertler, et al.
Targeted Disruption of the Murine zyxin Gene
Mol. Cell. Biol.,
January 1, 2003;
23(1):
70 - 79.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. F. Davies
Multiple Signaling Pathways in Flow-Mediated Endothelial Mechanotransduction: PYK-ing the Right Location
Arterioscler. Thromb. Vasc. Biol.,
November 1, 2002;
22(11):
1755 - 1757.
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|